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Identity 
Other names: MIRN331, hsa-mir-331 
HGNC (Hugo): MIR331 
Location: 12q22 
Local order: Genes flanking MIR331 on 12q22 are: 
- VEZT (vezatin) 
- METAP2 (methionyl aminopeptidase 2) 
DNA/RNA 
Description 
miR-331 is an intergenic microRNA gene. 
Transcription 
The primary transcript of miR-331 (pri-miR-331) is not 
currently known. 
Pre-microRNA-331 (Precursor microRNA) 
Accession: MI0000812 











Length: 22 nt 
Sequence: 26 - cuagguauggucccagggaucc - 47 
Mature miR-331-3p 
Accession: MIMAT0000760 
Length: 21 nt 
Sequence: 61 - gccccugggccuauccuagaa - 81 
Pseudogene 
No pseudogenes have been reported for miR-331. 
Protein 
Note 
N/A; microRNAs are not translated. 
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Mutations 
Note 




Five references have suggested a tumour suppressor 
role for miR-331 in prostate cancer.  
The first report demonstrated downregulation of miR-
331-3p in prostate cancer, and showed that this 
promoted ERBB-2 expression and AKT activity.  
Restoring miR-331-3p to prostate cancer cell lines 
reduced androgen receptor (AR) pathway signaling and 
PSA expression.  
Another report confirmed the reduced expression of 
miR-331-3p in aggressive prostate cancers.  
Two other studies showed that the RNA-binding 
protein HuR induces ERBB-2 expression in prostate 
cancer by preventing the degradation of ERBB-2 
mRNA by miR-331-3p, and that miR-331-3p inhibits 
the growth of prostate cancer cells in part by repressing 
expression of the deoxyhypusine hydroxylase (DOHH), 
an enzyme that controls the activity of the eukaryotic 
translation initiation factor eIF5A.  
In the latter study, an inverse correlation between miR-
331-3p and DOHH expression was observed in human 
prostate cancer tissues.  
A fifth publication confirmed that miR-331-3p is a 
prostate cancer tumour suppressor via its regulation of 
KLK4 expression in prostate cancer cells. 
Leukaemia 
Note 
Two references implicate miR-331 in leukaemia. One 
report showed that the levels of of miR-331-5p were 
inversely correlated with expression of P-glycoprotein, 
a drug resistance factor, in leukaemia cell lines with 
variable resistance to doxorubicin, and that transfection 
of these cell lines with miR-331-5p increased their 
sensitivity to doxorubicin. Lower levels of miR-331-5p 
were also detected in patients following treatment 
relapse.  
A second study reported that miR-331 was 
overexpressed in acute lymphocytic leukaemia (ALL) 
and chronic lymphocytic leukaemia (CLL), and it was 
speculated that miR-331 might have roles in 
haematopoiesis and leukaemogenesis by promoting 




One reference has suggested that miR-331-3p is a 
gastric cancer tumour suppressor. miR-331-3p was 
downregulated in gastric cancer cell lines, where  
transient overexpression of miR-331-3p reduced E2F1 
expression and blocked cell cycle progression. 
Liver cancer 
Note 
Increased circulating levels of miR-331 in a rat model 
of hepatocarcinogenesis suggest that miR-331 may 
have utility as a biomarker for the development and/or 
progression of liver cancer. 
Asbestos-related lung cancer 
Note 
One report identified miR-331-3p in a set of 
overexpressed miRNAs in asbestos-related lung cancer, 
suggesting that it might have diagnostic use. 
Natural killer (NK) cell activation 
Note 
Activation of NK cells by IL-2, IL-15 and IL-21 was 
shown to regulate expression of specific miRNAs in 
NK cells, including miR-331-3p. This suggested that 




miR-331 expression in cerebral ischaemia was 
regulated by the mood stabiliser and histone 
deacetylase inhibitor valproic acid (VPA), suggesting 
that it may have a role in this disease process. 
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